Johnson & Johnson vs Medtronic stock
Side by side in plain words: who keeps more of its sales, grows faster, costs less and owes less.
Johnson & Johnson is more profitable, is cheaper for its profits and has less debt. Medtronic grows faster.
Side by side
| Johnson & Johnson | Medtronic | |
|---|---|---|
| $651 billion | $128 billion | |
| 28.5% | 13.2% | |
| +2.7% | +3.8% | |
| 24.3× | 26.6× | |
| 0.7 years | 2.7 years | |
| 21.0% | 7.2% | |
| 2.3% | 3.5% |
How we compare
Four contests with the same rules as each stock page: profit kept from sales (higher wins), yearly sales growth across the last reports, up to five years (higher wins), price per unit of yearly profit (lower P/E wins; a company without profit loses) and debt in years of earnings (lower wins). A winner is only named when both companies have the number.
More comparisons: Johnson & Johnson vs Merck & · Johnson & Johnson vs Merck KGaA · Johnson & Johnson vs Moderna · Johnson & Johnson vs Novo Nordisk · Medtronic vs Eli Lilly · Medtronic vs McKesson · Medtronic vs Novo Nordisk · Medtronic vs Regeneron Pharmaceuticals

